ロード中...
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial
IMPORTANCE: Response patterns with immunotherapy may differ from those of other treatments. This warrants further investigation because some patients may benefit from continued immunotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)-defined first progression. OBJECTIVE: To evaluat...
保存先:
| 出版年: | JAMA Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5568541/ https://ncbi.nlm.nih.gov/pubmed/27243803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.0775 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|